Technical analyst Ashish Chaturmotha of Anand Rathi Securities has maintained 'buy' rating on Aurobindo Pharma Limited with a short term target of Rs 1350.

The analyst said that the stock can be purchased with a stop loss of Rs 1250.

Today, the stock of the company opened at Rs 1280 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 81.76 and 15.44 respectively.

Aurobindo Pharma Ltd, on Dec 03, declared that it has bagged tentative sanction from the USFDA to make and sell Duloxetine Hydrochloride Delayed Release Capsules in the editions of 20mg (base), 30mg (base) and 60mg (base).

Aurobindo Pharma has recorded a growth of 92.19% in its consolidated net profit of Rs 1,983.20 million for the three month period ended Sept. 30, 2010 as against Rs 1,031.90 million for the three month period ended Sept. 30, 2009,

Total income of the company surged 25.45% to Rs 11,232 million for the period under review from Rs 8,953.40 million for the quarter ended Sept 2010.